MétaCan
Menu
Back to cohort

Data from Natural History and Characteristics of <i>ERBB2</i>-mutated Hormone Receptor–positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case–control Study from AACR Project GENIE

2023· preprint· en· W4361958415 on OpenAlexafffund
Michele L. Lenoue-Newton, Sheau‐Chiann Chen, Thomas Stricker, David M. Hyman, Natalie Blauvelt, Philippe L. Bédard, Funda Meric‐Bernstam, Rinaa S. Punglia, Deborah Schrag, Eva M. Lepisto, Fabrice André, Lillian M. Smyth, Semih Doğan, Celeste Yu, Chetna Wathoo, Mia Levy, Lisa D. Eli, Feng Xu, Grace Mann, Alshad S. Lalani, Fei Ye, Christine Micheel, Mónica Arnedos

Bibliographic record

Venuenot available
Typepreprint
Languageen
FieldMedicine
TopicAdvanced Breast Cancer Therapies
Canadian institutionsPrincess Margaret Cancer Centre
FundersSheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer TherapyNational Center for Advancing Translational SciencesNational Cancer InstituteNational Institutes of HealthRobert J. Kleberg, Jr. and Helen C. Kleberg FoundationUnicancerVanderbilt UniversityInstitut Gustave-RoussyPuma BiotechnologyPrincess Margaret Cancer FoundationMemorial Sloan-Kettering Cancer CenterUniversity of Texas MD Anderson Cancer CenterCancer Prevention and Research Institute of TexasAmerican Association for Cancer Research
KeywordsBreast cancerCancerMedicineInternal medicineMetastatic breast cancerOncologyEndocrinology

Abstract

fetched live from OpenAlex

<div>AbstractPurpose:<p>We wanted to determine the prognosis and the phenotypic characteristics of hormone receptor–positive advanced breast cancer tumors harboring an <i>ERBB2</i> mutation in the absence of a HER2 amplification.</p>Experimental Design:<p>We retrospectively collected information from the American Association of Cancer Research-Genomics Evidence Neoplasia Information Exchange registry database from patients with hormone receptor–positive, HER2-negative, <i>ERBB2</i>-mutated advanced breast cancer. Phenotypic and co-mutational features, as well as response to treatment and outcome were compared with matched control cases <i>ERBB2</i> wild type.</p>Results:<p>A total of 45 <i>ERBB2</i>-mutant cases were identified for 90 matched controls. The presence of an <i>ERBB2</i> mutation was not associated with worse outcome determined by overall survival (OS) from first metastatic relapse. No significant differences were observed in phenotypic characteristics apart from higher lobular infiltrating subtype in the <i>ERBB2</i>-mutated group. <i>ERBB2</i> mutation did not seem to have an impact in response to treatment or time-to-progression (TTP) to endocrine therapy compared with <i>ERBB2</i> wild type. In the co-mutational analyses, <i>CDH1</i> mutation was more frequent in the <i>ERBB2-</i>mutated group (FDR < 1). Although not significant, fewer co-occurring <i>ESR1</i> mutations and more <i>KRAS</i> mutations were identified in the <i>ERBB2</i>-mutated group.</p>Conclusions:<p><i>ERBB2</i>-activating mutation was not associated with a worse OS from time of first metastatic relapse, or differences in TTP on treatment as compared with a series of matched controls. Although not significant, differences in coexisting mutations (<i>CDH1</i>, <i>ESR1</i>, and <i>KRAS</i>) were noted between the <i>ERBB2</i>-mutated and the control group.</p></div>

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.875
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0030.000
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0010.001
Research integrity0.0000.002
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.047
GPT teacher head0.314
Teacher spread0.266 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2023
Admission routes2
Has abstractyes

Explore more

Same topicAdvanced Breast Cancer TherapiesFrench-language works237,207